COVID vaccine companies told to focus on KP.2 variant for fall shots, per FDA announcement

close Video Dr. Marc Siegel on AstraZeneca withdrawing COVID-19 vaccine: I am concerned about the delay Fox News medical analyst Dr. Marc Siegel discusses AstraZeneca withdrawing its COVID-19 vaccine as concerns over side effects grow on 'Special Report.

' Join Fox News for access to this content Plus special access to select articles and other premium content with your account - free of charge. By entering your email and pushing continue, you are agreeing to Fox News' Terms of Use and Privacy Policy , which includes our Notice of Financial Incentive . Please enter a valid email address.

By entering your email and pushing continue, you are agreeing to Fox News' Terms of Use and Privacy Policy , which includes our Notice of Financial Incentive . Having trouble? Click here. The U.

S. Food and Drug Administration (FDA) has recommended that COVID vaccine manufacturers update their formulas for fall doses, in an attempt to target the KP.2 strain of the JN.

1 variant. The Thursday announcement came just a week after the agency’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted to recommend a " monovalent JN.1-lineage vaccine " at its June 5 meeting.

As of the end of March 2024, the KP.2 variant was responsible for just 4% of infections in the U.S.

, according to the COVID Data Tracker from the Centers for Disease Control and Prevention (CDC). CDC WARNS OF ‘DUAL MUTANT’ FLU STRAIN THAT COULD EVADE ANTIVIRAL DRUGS: ‘NEED TO CLOSELY MONITOR’ Meanwhile, .